Bristol-Myers & Pfizer Release Phase IV Data On Eliquis
Zacks Investment Research | Mar 18, 2019 06:44AM ET
Bristol-Myers Squibb Company (NYSE:BMY) along with partner Pfizer Inc. (NYSE:PFE) announced results from the phase IV -AUGUSTUS study evaluating the blood thinner drug, Eliquis (apixaban) versus vitamin K antagonists (VKAs). The study evaluates the safety of Eliquis as compared to warfarin or other VKA in patients with nonvalvular atrial fibrillation (NVAF) and a recent acute coronary syndrome (ACS) or for those undergoing percutaneous coronary intervention (PCI).
In the study, apart from Eliquis or VKA, patients were also randomized to aspirin or placebo and received a P2Y12 inhibitor. AUGUSTUS is the largest study in this high-risk patient population requiring both anticoagulant and antiplatelet therapies.
The study demonstrated that at six months, patients receiving a P2Y12 inhibitor with or without aspirin who were treated with Eliquis had lower rates of death or hospitalization and similar rates of death or ischemic events compared to those assigned to VKA. The results also showed that patients receiving a P2Y12 inhibitor and an anticoagulant who were treated with aspirin had similar rates of death or hospitalization and similar rates of death or ischemic events compared to those assigned to placebo.
Shares of Bristol-Myers have plunged 22.2% in the past year, against the industry ’s growth of 13.2%.
We remind investors that Eliquis is already approved for the reduction in the risk of stroke and systemic embolism in patients with NVAF, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and reduction in the risk of recurrent DVT and PE following initial therapy, and prophylaxis of DVT, which may lead to PE in patients who have undergone hip or knee replacement surgery.
Zacks Rank and Other Stocks to Consider
Bristol-Myers currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the healthcare sector are Celgene Corp. (NASDAQ:CELG) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) , While Celgene carries a a Zacks Rank #1 (Strong Buy), BioDelivery carries a Zacks Rank #2 (Buy). You can see .
Celgene’s earnings per share estimates have increased from $10.34 to $10.73 for 2019 and from $12.28 to $12.76 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.
Get The News You Want
BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 20 cents for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 16.53%.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.